1 in the alteplase group, five were considered
drug-related).
2 ients in the oral treatment group; none were
drug related.
3 during the study, but none of the deaths was
drug related.
4 In 5 these were considered
drug related.
5 .1 percentage points]); none were considered
drug related.
6 of drug, of which 21 (35%) were deemed to be
drug related.
7 serious adverse events suspected to be study
drug-related.
8 g the treatment period were considered to be
drug-related.
9 eated pooled, 1/4 placebo), with none deemed
drug-related.
10 quired corticosteroids, and none were deemed
drug-related.
11 ents leading to death; none were reported as
drug-related.
12 ary embolism (grade 4, suspected to be study
drug related)
4 days previously.
13 No patients had
drug-related acute hypertensive events during or after t
14 20 (6%) of 316 participants had study-
drug related adverse events in the tenofovir alafenamide
15 visit or hospital admission for either (1) a
drug related adverse medical event or overdose or (2) a
16 Drug-related adverse effects are manageable in most pati
17 Drug-related adverse effects were infrequent.
18 No serious
drug-related adverse effects were reported; other advers
19 All patients developed grade I
drug-related adverse effects, most commonly muscle spasm
20 ion of patients at risk for poor outcomes or
drug-related adverse effects, will ultimately help to ad
21 urgency was the most common grade 3-4 study
drug-related adverse event (two [1%] of 157 patients, bo
22 ofovir alafenamide discontinued because of a
drug-related adverse event (urticaria) after week 24.
23 open-label ceftriaxone phase, and no serious
drug-related adverse event occurred during the 12-week r
24 The most common
drug-related adverse event was decrease in neutrophil co
25 The most common
drug-related adverse event was headache.
26 The only
drug-related adverse event was hyperglycemia in patients
27 sease progression, 18 (<1%) were caused by a
drug-related adverse event, as assessed by the investiga
28 therapy because of disease progression or a
drug-related adverse event.
29 Fourteen patients had a serious
drug-related adverse event; of these patients, nine perm
30 vir group than the atazanavir group reported
drug-related adverse events (83 [33%] vs 121 [49%]) or a
31 Five patients (16%) experienced grade 3
drug-related adverse events (AEs); there were no grade 4
32 The most commonly reported
drug-related adverse events (grade 1 or 2) were nausea,
33 Eleven patients (61%) experienced
drug-related adverse events (mostly grade 1-2); none dis
34 The most common
drug-related adverse events (those that occurred in >/=1
35 will continue to monitor device-related and
drug-related adverse events and encourages active survei
36 rug exposure might lessen the possibility of
drug-related adverse events and may also prevent the dev
37 There were no
drug-related adverse events and no drug-related deaths.
38 Incidences of
drug-related adverse events for micafungin and standard
39 primary safety outcome was the occurrence of
drug-related adverse events in mothers and infants until
40 Five (1%) participants died because of
drug-related adverse events in the ipilimumab group; thr
41 The most common
drug-related adverse events included abdominal pain (fiv
42 Other common
drug-related adverse events included arm swelling or oed
43 The most common grade >/=3
drug-related adverse events included myelosuppression an
44 No
drug-related adverse events led to treatment discontinua
45 ry tapering or treatment discontinuation for
drug-related adverse events may not only reduce patients
46 to 160 mg/day regorafenib) if no significant
drug-related adverse events occurred and a standard-dose
47 A few
drug-related adverse events occurred and were similar ac
48 Drug-related adverse events occurred in 103 (20%) partic
49 Drug-related adverse events occurred in 130 (24%) of 531
50 Drug-related adverse events occurred in 15.0% of fidaxom
51 Drug-related adverse events occurred in 185 patients (21
52 Drug-related adverse events occurred in 51 (63%) patient
53 More grade 2-4
drug-related adverse events occurred with ritonavir-boos
54 Numerically, more
drug-related adverse events occurred with the three-drug
55 Drug-related adverse events of any grade and of grade 3
56 The most common
drug-related adverse events of any grade in the 2 mg/kg
57 Drug-related adverse events of grade 3 or 4 occurred in
58 Drug-related adverse events of grade 3 or 4 were reporte
59 The most common
drug-related adverse events of grade 3 or higher were ne
60 Drug-related adverse events of grade 3 or higher were re
61 associated with an increased risk of serious
drug-related adverse events or mortality.
62 Drug-related adverse events such as asthenia, poor appet
63 taking darunavir (30 [20%] participants) had
drug-related adverse events than those on lopinavir (eig
64 Frequency of
drug-related adverse events was comparable between defer
65 o 0.26), but the probability of grade 3 or 4
drug-related adverse events was higher with systematic t
66 Drug-related adverse events were all of mild intensity a
67 Common
drug-related adverse events were diarrhea, skin rash, hy
68 The most common
drug-related adverse events were diarrhoea (23/242 [10%]
69 The most common
drug-related adverse events were fatigue, nausea, diarrh
70 The most common
drug-related adverse events were headache (11 participan
71 The most common (n>1)
drug-related adverse events were headache (in nine [30%]
72 The most common grade 3 or 4
drug-related adverse events were increased concentration
73 Grade 3 or 4
drug-related adverse events were infrequent and included
74 All
drug-related adverse events were known toxicities associ
75 Study
drug-related adverse events were less common in the bict
76 Drug-related adverse events were less common with rifamp
77 as similar between the two groups, but study
drug-related adverse events were more common in the teno
78 le was much the same in each group, although
drug-related adverse events were more common with losmap
79 The most common
drug-related adverse events were nausea (39 [7%] vs 18 [
80 The most common study
drug-related adverse events were nausea (in ten particip
81 No
drug-related adverse events were noted; procedure-relate
82 Results: No
drug-related adverse events were observed throughout the
83 No study
drug-related adverse events were observed.
84 The most frequent grade 3 or 4
drug-related adverse events were rash or acne (31 [10%]
85 m)Tc-PHC-102 was well tolerated and no study
drug-related adverse events were recorded.
86 During the first 12 months of follow-up, 54
drug-related adverse events were reported (51 mild, thre
87 Drug-related adverse events were reported by 13 (41%) of
88 Study
drug-related adverse events were reported for 64 (20%) p
89 Study
drug-related adverse events were reported for 89 (28%) p
90 Serious
drug-related adverse events were reported in 108 (43%) p
91 Drug-related adverse events were reported in 109 (42%) p
92 ts remained virologically suppressed, and no
drug-related adverse events were reported.
93 Serious
drug-related adverse events were seen in three patients
94 Common
drug-related adverse events were thrombocytopenia (43%),
95 5 or 60 mg/m(2) The most common grade 3 to 4
drug-related adverse events were thrombocytopenia (47%),
96 Drug-related adverse events were usually of grade 1 or 2
97 ted and those of grade 3 or worse, and study
drug-related adverse events, analysed in all patients wh
98 The primary endpoint was incidence of
drug-related adverse events, analysed in all randomly as
99 We report completion,
drug-related adverse events, and active tuberculosis inc
100 The most common
drug-related adverse events, headache and an elevated la
101 ith 10 (17%) of 60 patients having grade 3-4
drug-related adverse events, the most common of which we
102 12 (2%) discontinued selpercatinib owing to
drug-related adverse events.
103 3%) patients required dose reductions due to
drug-related adverse events.
104 compared with voriconazole, with fewer study-
drug-related adverse events.
105 s was shown in the occurrence of serious and
drug-related adverse events.
106 in each group discontinued treatment due to
drug-related adverse events.
107 0.56 [95% CI, .41-.75]) but no difference in
drug-related adverse events.
108 Five patients (1%) died due to
drug-related adverse events.
109 There were no differences in serious
drug-related adverse events.
110 Bq and was safe, well tolerated, and without
drug-related adverse events.
111 Four patients discontinued (two because of
drug-related adverse events: elevated liver transaminase
112 injury, Clostridium difficile infection, or
drug-related adverse reactions requiring discontinuation
113 (<1%) participant discontinued due to study
drug related AE(s).
114 (<1%) participant discontinued due to study
drug-related AE.
115 inuation in 5.6% and 8.2%, respectively; and
drug-related AEs (none fatal) in 11.7% and 9.7%, respect
116 Rates of
drug-related AEs for DOR, DRV+r, and EFV were 30.9%, 32.
117 actam and 31% of colistin+imipenem patients,
drug-related AEs in 16% and 31% (no drug-related deaths)
118 The most frequently reported
drug-related AEs were micturition urgency (n = 16; 40%),
119 se events (AEs), discontinuations because of
drug-related AEs, dose-limiting toxicities, or antidrug
120 The relationship of
drug-related affective sequelae to non-drug reward proce
121 Many hypotensive episodes in the ICU are
drug related and require treatment.
122 ns between place or context and reward, both
drug-related and natural.
123 ns (33%) were low, no serious AEs were study
drug related,
and 1 (<1%) participant discontinued due t
124 adverse events, none of which was considered
drug related,
and three (7%) patients died more than 30
125 ns (33%) were low, no serious AEs were study
drug-related,
and 1 (<1%) participant discontinued due t
126 state-related (conscious vs unconscious) or
drug-related (
anesthetic vs no anesthetic) effects.
127 tudy because of adverse events (64 [3%] were
drug-related),
as assessed by the investigator, and 171
128 To differentiate the state-related and
drug-related associations of cortical connectivity and d
129 tem, and evidence suggests that it modulates
drug-related behavior.
130 ating HCRT receptor 1 (HCRT-R1) signaling in
drug-related behaviors for all major drug classes, inclu
131 (D2R-MSN) can exert antagonistic effects in
drug-related behaviors, and display distinct alterations
132 ate early gene Egr3 has long-term effects on
drug-related behaviors.
133 GTPases has not been extensively examined in
drug-related behaviors.
134 rders but without the confounding effects of
drug-related brain changes.
135 ss and keratitis), which were not considered
drug related by the respective investigators.
136 ced age, and prior diagnoses contributing to
drug related cardiotoxicity.
137 When a
drug-related cause was suspected, an objective assessmen
138 ied of liver cancer (odds ratio [OR] = 9.2),
drug-related causes (OR = 4.3), and cirrhosis (OR = 3.7)
139 e range, 2.1-9.1) of follow-up: 18.7% due to
drug-related causes, 55.8% due to HIV-related causes, an
140 ional hypotension was assessed for suspected
drug-related causes.
141 s of drugs were next analyzed with regard to
drug-related characteristics and their physicochemical p
142 wo patients in the PGA group exited owing to
drug-related complications (1 patient with uveitis and 1
143 High-risk prescribing and preventable
drug-related complications are common in primary care.
144 cause, as well as for UC-related and UC- or
drug-related complications, compared with placebo.
145 ing benzydamine, tamoxifen, and thioanisole,
drug-related compounds known to be also accepted by huma
146 le in addictive disorders and is involved in
drug-related craving.
147 These data provide novel insight into
drug-related cross-generational epigenetic effects, and
148 We found that exposure to
drug-related cues reinstated cocaine-seeking behavior an
149 ctors for craving and use include stress and
drug-related cues.
150 ch relapse is often initiated by exposure to
drug-related cues.
151 With increasing availability of
drug-related data, our package will open new avenues of
152 ndently protected against HIV-related death,
drug-related death and death due to other causes.
153 ase and control group in terms of AE, and no
drug-related death occurred.
154 One
drug-related death was noted.
155 p were deemed by investigators to have had a
drug-related death.
156 There were no
drug-related deaths due to treatment-emergent adverse ev
157 Rising
drug-related deaths had a much smaller effect: 0.1 y in
158 There were four (<1%)
drug-related deaths in the sorafenib group and two (<1%)
159 No
drug-related deaths were observed.
160 No
drug-related deaths were recorded but 16 (62%) patients
161 No
drug-related deaths were reported.
162 ase of 12.8% (95% CI 11.0-14.6; p<0.0001) in
drug-related deaths within counties.
163 atients, drug-related AEs in 16% and 31% (no
drug-related deaths), and treatment-emergent nephrotoxic
164 There were no study
drug-related deaths.
165 There were no
drug-related deaths.
166 nations for the stall have focused on rising
drug-related deaths.
167 e were no drug-related adverse events and no
drug-related deaths.
168 opioids have become the number one cause of
drug-related deaths.
169 associated with a more than 50% increase in
drug-related deaths.
170 basis for a brain-based characterization of
drug-related decision making in drug abuse, including ef
171 ted disorder (aHR, 3.45; 95% CI, 3.19-3.72),
drug-related disorder (aHR, 6.84; 95% CI, 6.32-7.40), su
172 Cocaine dependence impacts
drug-related,
dopamine-dependent reward processing, yet
173 ade 3 or higher clinical AEs (1 subject with
drug-related [
DR] psychomotor hyperactivity and insomnia
174 state-related (conscious vs unconscious) or
drug-related (
drug vs no drug).
175 uscular Research Group (CINRG) and evaluated
drug-related effects of vamorolone on motor outcomes and
176 nue using cocaine for reasons beyond desired
drug-related effects.
177 uded discharge functional status and adverse
drug-related effects.
178 verse events that were suspected to be study
drug-related (
eltrombopag: acute kidney injury, arterial
179 tion was cholestatic in pattern; 8 (21%) had
drug-related enzyme elevations.
180 No
drug-related events leading to discontinuation were note
181 es were considered to have definite/probable
drug-related events within the spectrum of IOI, retinal
182 Recent research shows that rewarding
drug-related experiences induce synchronous activation o
183 We found that in addition to
drug-related factors, age and history of diabetes were i
184 Other
drug-related G3 and G4 events included anemia, leukopeni
185 ing the treatment period.RESULTSThere were 9
drug-related gastrointestinal adverse events that resolv
186 There were no
drug-related Grade >3 adverse events.
187 Drug-related grade >=2 adverse events and withdrawals du
188 Drug-related grade 3 or 4 adverse events occurred in 15%
189 The most common
drug-related grade 3 or 4 adverse events were neutropeni
190 The most common
drug-related grade 3 or 4 treatment-emergent adverse eve
191 The most common
drug-related grade 3 or worse treatment-emergent adverse
192 he 2 mg/kg pembrolizumab group, was the only
drug-related grade 3 to 4 adverse event reported in more
193 The most frequent
drug-related grade 3-4 adverse events included neutropen
194 ents were regarded by the investigator to be
drug-related (
grade 2 lymphostasis and grade 2 lymphoede
195 use a criminal behaviour, and seek to reduce
drug-related harm at the population level.
196 actors exist that increases vulnerability to
drug-related harms from injection drug use, including bl
197 o as a "drug-related hazardous condition." A
drug-related hazardous condition is the temporal gap (in
198 s considered drug induced, referred to as a "
drug-related hazardous condition." A drug-related hazard
199 th volasertib experienced more grade 3 and 4
drug-related hematologic adverse events (AEs) and fewer
200 one patient in the gefitinib group died from
drug-related hepatic and renal failure.
201 isease include viral hepatitis coinfections,
drug-related hepatotoxicity, fatty liver disease, and di
202 Drug-related improvements in OS were, however, widely di
203 n North Carolina, the full scope of invasive
drug-related infections (IDRIs) has not.
204 Compared with those who had non-
drug-related infections, patients with IDRIs were younge
205 erogeneous network, which integrates diverse
drug-related information.
206 8 of 32 patients discontinued lenvatinib for
drug-related issues.
207 A
drug-related linear increase in the amplitude of the fro
208 toxicity are essential to predict unexpected
drug-related liver injury.
209 During transport to the ESI source
drug related material was completely extracted from the
210 sured in the assay (intact drug and/or other
drug related material).
211 Parent drug accounted for 25% of
drug-related material, whereas that of the catabolites [
212 A combined total of 227
drug-related materials (DRM) were detected from all eigh
213 The association between
drug-related mortality and income and incarceration pers
214 with buprenorphine had reduced all-cause and
drug-related mortality during the first 4 weeks of treat
215 For the remaining time on treatment,
drug-related mortality risk did not differ (adjusted MRR
216 ion, all-cause mortality did not differ, but
drug-related mortality was lower for methadone (adjusted
217 0; p<0.0001) and 2.6% (2.1-3.1; p<0.0001) in
drug-related mortality, respectively.
218 es which genetic factors are associated with
drug-related movement disorders (DRMD), in an attempt to
219 sted all-cause MRR 1.12, 0.79-1.59; adjusted
drug-related MRR 0.50, 0.29-0.86).
220 l-cause MRR 2.17, 95% CI 1.29-3.67; adjusted
drug-related MRR 4.88, 1.73-13.69).
221 erence being driven by a higher incidence of
drug-related nausea in the dolutegravir, abacavir, and l
222 of the alloimmune response, whereas reducing
drug-related nephrotoxicity.
223 Sexual dimorphism in
drug-related neuroanatomic changes and brain-behavior re
224 No cases of paradoxical
drug-related neurological worsening were recorded.
225 enital or late onset, stable or progressive,
drug related,
noise induced, age related, traumatic or p
226 tment arm, and pleural effusion was the only
drug-related,
nonhematologic adverse event reported more
227 self-inflicted injury should be extended to
drug-related or alcohol-related and violent injury in ad
228 girls, and 3.15 [2.73-3.63] for boys) and of
drug-related or alcohol-related death (4.71 [3.28-6.76]
229 tion should address the substantial risks of
drug-related or alcohol-related death alongside risks of
230 Risks of
drug-related or alcohol-related death increased by a sim
231 index injury, risks of suicide and risks of
drug-related or alcohol-related death were increased by
232 ] for girls, and 6.20 [5.27-7.30] for boys),
drug-related or alcohol-related injury (4.55 [3.23-6.39]
233 sks of death in five causal groups (suicide,
drug-related or alcohol-related, homicide, accidental, a
234 dversity-related injury (ie, self-inflicted,
drug-related or alcohol-related, or violent injury) affe
235 following adversity-related (self-inflicted,
drug-related or alcohol-related, or violent injury) or a
236 19 (27%) of 71 patients had study
drug-related or procedure-related serious adverse events
237 ar trajectory was associated with all-cause,
drug-related,
or human immunodeficiency virus (HIV)-rela
238 s, continuum of HIV care, sexual risk, and 5
drug-related outcomes (sharing injection equipment, inje
239 eatment by comparing all-cause mortality and
drug-related overdose mortality at treatment induction,
240 ude mortality rates (CMRs) for all-cause and
drug-related overdose mortality, and mortality rate rati
241 phine reduces mortality risk, especially for
drug-related overdose.
242 iple-therapy group were possibly or probably
drug related (
p=0.007).
243 s cardiovascular, respiratory, neurological,
drug related,
patient injury, death, or unexpected admis
244 Grade 1/2
drug-related peripheral neuropathy occurred in 12% (no g
245 We examined all-cause mortality (ACM),
drug-related poisoning (DRP) mortality, and mortality no
246 Multiple patient-, design-, and
drug-related potential predictors of response were analy
247 antithrombotic therapy emerged as the single
drug-related predictor of GIB in addition to patient-rel
248 summarize the representative applications in
drug-related problems.
249 Current studies typically use either only
drug-related properties (e.g. chemical structures) or on
250 nced adverse events that were possibly study-
drug related:
pyrexia and intraocular inflammation that
251 60 patients; one patient developed a grade 3
drug-related rash.
252 erential diagnosis includes lichen planus, a
drug-related reaction, and viral infection.
253 atural reward behaviors can alter subsequent
drug-related reward.
254 l cortex associated with the anticipation of
drug-related rewards (cigarette puff).
255 ddiction is associated with overvaluation of
drug-related rewards and undervaluation of natural, nond
256 k force formed to monitor device-related and
drug-related safety events.
257 There were no new
drug-related safety signals.
258 One
drug-related serious adverse event occurred in a patient
259 14 patients had at least one
drug-related serious adverse event: six patients in the
260 No
drug-related serious adverse events (AEs), discontinuati
261 enofovir disoproxil fumarate group had study
drug-related serious adverse events (potential drug-indu
262 We observed no
drug-related serious adverse events after more than 6000
263 There were no
drug-related serious adverse events and no treatment-rel
264 We noted grade 3-4
drug-related serious adverse events in 12 (5%) nivolumab
265 Drug-related serious adverse events occurred in 28 (38%)
266 No
drug-related serious adverse events were observed.
267 peared to be well tolerated and safe, and no
drug-related serious adverse events were reported.
268 Potentially
drug-related serious adverse events within 42 days of st
269 tocols but also a potentially higher rate of
drug-related serious adverse events.
270 We detected no
drug-related serious adverse events.
271 ion use (MD -2.04; 95%CI -3.19 to -0.88) and
drug-related serious AEs (RR 0.77; 95%CI 0.20 to 2.91).
272 part 1, 117 adverse events were reported; no
drug-related serious or severe events were reported.
273 No
drug-related serious treatment-emergent adverse events o
274 hould range from benign diseases and various
drug related side effects to severe disorders, such as p
275 ould potentially provide a means of reducing
drug related side effects whilst maintaining, or perhaps
276 MAC-PD is difficult to treat, with frequent
drug-related side effects and suboptimal treatment outco
277 Furthermore, 24 patients had
drug-related side effects from the liver and pancreas.
278 taging system designation; type and grade of
drug-related side effects; response to treatment; durati
279 Drug-related skin and gastrointestinal disorders of any
280 5, 95% confidence interval (CI): 1.14, 1.59;
drug-related SMR: 4.60, 95% CI: 3.17, 6.46; HIV-related
281 s to fearful stimuli, stressful stimuli, and
drug-related stimuli.
282 l separations, biosensing, cell studies, and
drug-related studies.
283 how the networks can be used to investigate
drug-related systems.
284 d how graph convolution networks can help in
drug-related tasks.
285 Serious
drug-related TEAEs occurred in 13 (9%) of 148 patients.
286 ldbearing potential because of antiepileptic
drug-related teratogenicity and hormonal interactions; a
287 applications, and discussion of vaccine- and
drug-related terminology and drug studies.
288 hange the EV emission profiles reflective of
drug-related therapeutic stress.
289 est that clinical trials of immunomodulatory
drugs related to CTLA4 and that are already Food and Dru
290 tients could switch treatment in the case of
drug-related toxic effects or absence or loss of respons
291 inical recovery and minimizing the effect of
drug-related toxic effects.
292 No patients died from
drug-related toxic effects.
293 h the combination arm and included one fatal
drug-related toxicity (intestinal occlusion).
294 ot have equivalent susceptibility to serious
drug-related toxicity (SDRT).
295 demonstrated good tolerability without clear
drug-related toxicity, although the number and duration
296 til disease progression or intolerable study
drug-related toxicity.
297 There were no
drug-related treatment discontinuations due to ledipasvi
298 No
drug-related trends in safety parameters were identified
299 digms of 'simulated' drug choice (choice for
drug-related vs affectively pleasant, unpleasant, and ne
300 Serious adverse events suspected to be study
drug related were reported in eight (11%) patients in th